Volume 5, Issue 3 (1-2004)                   yafte 2004, 5(3): 57-61 | Back to browse issues page

XML Persian Abstract Print

Abstract:   (12415 Views)
Introduction: Chronic prostatitis is an obtrusive, annoying and common disease that many people are suffering from it, and it is followed by complicated problems for the patient and the treating physician because of recrudescence of the disease. Materials and Methods: In this interventional study 20 patients with prostatitis, who had no satisfactory answer to the common pharmacotherapy, were selected randomly and were candidate for surgery, before operation the patients’ personal information and their disease symptoms were recorded in a special questionnaire, then patients were put in current of surgery procedures and its probable complications, and finally in case of written satisfaction of the patients, they undergo TUI surgery. After six months from operation and later follows- up, before and after operation the symptoms were compared. The criteria for studying evident symptoms of chronic prostatitis include: nocturia, polyuria, irritation of urine, caliber and unnormal flow of urine, drop by drop urination at the end of urination, pain during intercourse, return of ejaculation into bladder (probable complication of the surgery) and sexuality disorder. Gathered data was analyzed using Wilcoxon test. Findings: Results showed that patients treated with TUI returned to a good state of health significantly in comparison with their condition before the surgery. Evident symptoms of chronic prostatitis reduced (p>0.05) significantly too. The patients were quite satisfied, as well as need for pharmacotherapy decreased significantly. Conclusion: TUI is recommended as a suitable alternative treatment for patients with chronic prostatitis resistant to pharmacotherapy.
Full-Text [PDF 192 kb]   (7972 Downloads)    
Type of Study: Research |
Received: 2013/01/8 | Accepted: 2021/07/12 | Published: 2004/01/15

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.